436 related articles for article (PubMed ID: 27973438)
21. Long-term effects of aerobic plus resistance training on the adipokines and neuropeptides in nonalcoholic fatty liver disease obese adolescents.
de Piano A; de Mello MT; Sanches Pde L; da Silva PL; Campos RM; Carnier J; Corgosinho F; Foschini D; Masquio DL; Tock L; Oyama LM; do Nascimento CM; Tufik S; Dâmaso AR
Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1313-24. PubMed ID: 22932160
[TBL] [Abstract][Full Text] [Related]
22. Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis.
Simon Y; Kessler SM; Gemperlein K; Bohle RM; Müller R; Haybaeck J; Kiemer AK
World J Gastroenterol; 2014 Dec; 20(47):17839-50. PubMed ID: 25548482
[TBL] [Abstract][Full Text] [Related]
23. Circulating ghrelin and leptin concentrations and growth hormone secretagogue receptor abundance in liver, muscle, and adipose tissue of beef cattle exhibiting differences in composition of gain.
Jennings JS; Wertz-Lutz AE; Pritchard RH; Weaver AD; Keisler DH; Bruns K
J Anim Sci; 2011 Dec; 89(12):3954-72. PubMed ID: 21724941
[TBL] [Abstract][Full Text] [Related]
24. From chronic overnutrition to insulin resistance: the role of fat-storing capacity and inflammation.
Lionetti L; Mollica MP; Lombardi A; Cavaliere G; Gifuni G; Barletta A
Nutr Metab Cardiovasc Dis; 2009 Feb; 19(2):146-52. PubMed ID: 19171470
[TBL] [Abstract][Full Text] [Related]
25. Evidence for adipose-muscle cross talk: opposing regulation of muscle proteolysis by adiponectin and Fatty acids.
Zhou Q; Du J; Hu Z; Walsh K; Wang XH
Endocrinology; 2007 Dec; 148(12):5696-705. PubMed ID: 17761767
[TBL] [Abstract][Full Text] [Related]
26. [Insulin resistance in non-alcoholic fatty liver disease].
Park JH
Korean J Hepatol; 2006 Mar; 12(1):16-30. PubMed ID: 16565603
[TBL] [Abstract][Full Text] [Related]
27. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones.
Meek CL; Lewis HB; Reimann F; Gribble FM; Park AJ
Peptides; 2016 Mar; 77():28-37. PubMed ID: 26344355
[TBL] [Abstract][Full Text] [Related]
28. Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers.
Al-Muzafar HM; Amin KA
BMC Complement Altern Med; 2017 Jan; 17(1):43. PubMed ID: 28086768
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines.
Panera N; Della Corte C; Crudele A; Stronati L; Nobili V; Alisi A
Expert Rev Gastroenterol Hepatol; 2016; 10(3):393-403. PubMed ID: 26654761
[TBL] [Abstract][Full Text] [Related]
30. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care--correlations with food intake, metabolism, exercise capacity, and hormones.
Fouladiun M; Körner U; Bosaeus I; Daneryd P; Hyltander A; Lundholm KG
Cancer; 2005 May; 103(10):2189-98. PubMed ID: 15822132
[TBL] [Abstract][Full Text] [Related]
31. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
Larter CZ; Yeh MM; Haigh WG; Van Rooyen DM; Brooling J; Heydet D; Nolan CJ; Teoh NC; Farrell GC
Obesity (Silver Spring); 2013 Jun; 21(6):1189-99. PubMed ID: 23666886
[TBL] [Abstract][Full Text] [Related]
32. [Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes].
Huang Y; Fu JF; Shi HB; Liu LR
Zhonghua Er Ke Za Zhi; 2011 Feb; 49(2):139-45. PubMed ID: 21426695
[TBL] [Abstract][Full Text] [Related]
33. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
Chen S; Zhao X; Ran L; Wan J; Wang X; Qin Y; Shu F; Gao Y; Yuan L; Zhang Q; Mi M
Dig Liver Dis; 2015 Mar; 47(3):226-32. PubMed ID: 25577300
[TBL] [Abstract][Full Text] [Related]
34. Serum palmitoleate acts as a lipokine in subjects at high cardiometabolic risk.
Merino J; Sala-Vila A; Plana N; Girona J; Vallve JC; Ibarretxe D; Ros E; Ferré R; Heras M; Masana L
Nutr Metab Cardiovasc Dis; 2016 Mar; 26(3):261-7. PubMed ID: 26817937
[TBL] [Abstract][Full Text] [Related]
35. Non-alcoholic fatty liver disease pathogenesis: the present and the future.
Petta S; Muratore C; Craxì A
Dig Liver Dis; 2009 Sep; 41(9):615-25. PubMed ID: 19223251
[TBL] [Abstract][Full Text] [Related]
36. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C
World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998
[TBL] [Abstract][Full Text] [Related]
37. Altered distribution of regulatory lymphocytes by oral administration of soy-extracts exerts a hepatoprotective effect alleviating immune mediated liver injury, non-alcoholic steatohepatitis and insulin resistance.
Khoury T; Ben Ya'acov A; Shabat Y; Zolotarovya L; Snir R; Ilan Y
World J Gastroenterol; 2015 Jun; 21(24):7443-56. PubMed ID: 26139990
[TBL] [Abstract][Full Text] [Related]
38. Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease.
Gaemers IC; Stallen JM; Kunne C; Wallner C; van Werven J; Nederveen A; Lamers WH
Biochim Biophys Acta; 2011 Apr; 1812(4):447-58. PubMed ID: 21216282
[TBL] [Abstract][Full Text] [Related]
39. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
[TBL] [Abstract][Full Text] [Related]
40. A concise review of non-alcoholic fatty liver disease.
Than NN; Newsome PN
Atherosclerosis; 2015 Mar; 239(1):192-202. PubMed ID: 25617860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
